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Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy. It is the fourth leading cause of 
cancer-related death in the United States and second only to colorectal cancer as a cause of digestive 
cancer-related death.1 Surgical resection is the only potentially curative treatment. Unfortunately, because 
of the late presentation, only 15 to 20 percent of patients are candidates for surgical intervention. 
Furthermore, prognosis is poor, even after a complete resection. Five-year survival after 
pancreaticoduodenectomy is about 25 to 30 percent for node-negative and 10 percent for node-positive 
disease. On the other hand, advancements in radiologic and endoscopic ultrasound imaging have improved 
our ability to detect and stage pancreatic cancer allowing for more selective surgical intervention for patients 
with “resectable disease”. In most patients, palliative therapy and efforts to prolong life and maximize the 
quality of life are the major goals. 
 
In this article, we will review our multidisciplinary approach for patients with pancreatic cancer.  Specifically, 
we will review the epidemiology, diagnosis and staging, biliary drainage techniques, selection of patients 
for surgery, chemotherapy, radiation therapy and discuss other palliative interventions. The areas of active 
research investigation and where our knowledge is limited will be emphasized. 
 
Background and Epidemiology 
 
PDAC is the 4th leading cause of cancer-related mortality in the United States. Over 45,000 patients are 
diagnosed each year in the US, and the majority of these patients succumb to their disease. Eighty percent 
of patients are diagnosed with advanced, unresectable disease. According to the latest statistics from the 
American Cancer Society,2 only 7% of patients survive 5 years after diagnosis. While the 5-year survival 
rate improves to 25% in patients presenting with stage 1 or localized disease, only 9% of patients are 
identified at this early stage.2 The majority of patients (53%) presents with distant, metastatic disease, and 
have a 5-year survival of 2%.3 Identification of risk factors and establishing earlier detection methods are 
therefore of paramount importance. Smoking and obesity are modifiable risk factors. However, an 
increased incidence of PDAC is also noted with advanced age, as 2/3 of patients are greater than age 65. 
Men are 30% more likely to develop PDAC than women, with African Americans more commonly affected 
than Caucasians.2 Chronic pancreatitis also increases this risk,4 and a recent meta-analysis3 found that the 
pooled relative risk for PDAC in chronic pancreatitis was 13.3 (95% CI: 6.1-28.9). This relative risk is even 
higher in hereditary pancreatitis and tropical pancreatitis, suggesting that patients who present earlier with 
chronic pancreatitis are at increased risk for PDAC. Patients with longstanding type 2 diabetes have an 
approximate two-fold increase in PDAC5-7 and Helicobacter pylori infection8 has also been found to 
associate with PDAC. While the majority of patients have sporadic disease, recent advances in genome 
sequencing have identified mutations in PALB2, BRCA2, STK11/LKB1 and P16 and an increased incidence 
of PDAC.9-11 Despite this improvement in knowledge of PDAC and its risk factors, no therapy has been 
identified that significantly alters the course of the disease, particularly since early diagnosis remains 
problematic. The absence of reliable blood markers for PDAC reduces the potential effectiveness of a 
screening strategy in high-risk patients. The discovery of a biomarker that would facilitate identification of 
PDAC would greatly affect patient management and prognosis. To date, there is no established screening 
test, although patients with significant family history might undergo close observation with abdominal 
magnetic resonance imaging (MRI) and endoscopic ultrasound (EUS).12 Further study is clearly needed in 
this area.  
 




In most institutions, computed tomography (CT) is the primary modality for staging of suspected PDAC. 
Pancreas protocol CT entails several alterations to routine abdominal CT. CT should be performed with 
rapid injection of intravenous iodinated contrast, ideally at a rate of at least 4 ml/s. Slices should be 
reconstructed at less than or equal to 3 mm with overlap. At least two post-contrast acquisitions, in the late 
arterial (or parenchymal) and venous phases are useful to assess the arteries (celiac, common hepatic, 
peripancreatic and superior mesenteric arteries) and veins (portal, splenic and superior mesenteric veins). 
The parenchymal phase best shows the tumor as an ill-defined hypodense mass in the pancreatic 
parenchyma (Figure 1), while the venous phase is best for detecting liver metastases. Neutral enteral 
contrast such as water is helpful, since this allows for better identification of the duodenal wall compared to 
positive enteral contrast, and results in artifact-free reformations. In many centers no oral contrast is used. 
Coronal and sagittal reformations in both arterial and venous phases increase the sensitivity for determining 
local invasion. Maximum intensity projection images are helpful in identifying variant vascular anatomy. 
Curved reformations may be helpful in staging PDAC, though we do not produce these on a routine basis. 
 
MRI is also useful for diagnosis and staging of PDAC though not proven to be superior to CT. The most 
important sequence is dynamic post-gadolinium series.  
 
Diagnosis of PDAC 
 
CT is reported to have a sensitivity of 89-97% for PDAC, though it is less effective in diagnosing small (< 2 
cm) lesions with a sensitivity of 65-75%.13 In this respect endoscopic ultrasound is superior. About 10% of 
pancreas cancers are not discerned as a mass (i.e. they are isodense to pancreas). The only clue to the 
presence of PDAC may be an abrupt cut off of the pancreatic duct, particularly if there is upstream glandular 
atrophy.14 Other secondary imaging features may include a distal bile duct stricture and abnormal bulge to 
the contour of the gland, although these features are non-specific and may be seen in benign pathology 
(eg. chronic pancreatitis). Accuracy of diagnosis is improved if CT is performed prior to biliary stenting, 
since artifact from a stent may make it difficult to identify the tumor in the pancreatic head. 
 
PDAC is hypointense to adjacent parenchyma on pre-contrast and initial post-contrast MRI. In late post-
contrast MRI, the tumor may show delayed enhancement and may become isointense. The finding of a 
non-occluded duct within a mass-like lesion in the pancreas is termed the “duct penetrating sign”. This sign 
is thought to be specific for a benign lesion, such as chronic pancreatitis or autoimmune pancreatitis. 
 
Staging of PDAC 
 
Surgical resection with negative margins (R0 resection) is the only potentially curative treatment for PDAC, 
but only 15% to 20% of patients present with potentially resectable disease (see “Surgical Approaches to 
PDAC”, below). In order to increase the chances of R0 resection, venous resection and reconstruction are 
increasingly performed.13,15 As a result, the American Joint Commission on Cancer considers isolated 
venous invasion as T3 disease (locally advanced but potentially resectable) while arterial invasion is 
deemed unresectable (T4 disease).13,14 The concept of borderline resectability has also been raised 
recently. This entity includes patients with advanced venous invasion or early invasion of the hepatic artery 
in whom a trial of chemo-radiotherapy is initiated.16,17 Surgery is only considered if there is a good response 
to the neoadjuvant therapy.  
 
Current criteria for resectability include absence of distant metastases, absence of tumor involvement of 
major arteries, and no venous invasion. If there is venous involvement, the vein should be patent and 
important venous branches such as jejunal veins should not be involved. Criteria of venous resectability 
may vary based on the surgeon’s performance and experience.  
 
In general, a vessel is said to be invaded if more than 180-degree circumference is contiguous with the 
tumor. Such a CT or MRI finding is 45-84% sensitive and 98-100% specific for vascular invasion (Figure 
2).13,14 Vessel deformity (teardrop sign) is also considered a sign of invasion, even if the tumor has less 
than a 180-degree footprint on the vessel. A sign that is relatively underutilized is the dilation of 
peripancreatic veins. The anterior and posterior superior pancreaticoduodenal veins and the gastrocolic 
trunk form an arcade around the pancreatic head and invasion of any part of this arcade may lead to venous 
engorgement.  
 
CT is not sensitive for detecting nodal metastases. Using a short axis dimension of 10 mm as the cut-off, 
CT has a sensitivity of only 15% for detecting nodal metastases.13,14 Using a 5 mm threshold, sensitivity 
increases to about 70% but specificity drops to 65%. On the other hand, enlarged nodes may be secondary 
to pancreatitis, chronic liver disease or other benign processes.  
 
CT is also inaccurate in detecting small hepatic and peritoneal metastases. Up to a third of patients with no 
obvious metastases on a high-quality CT may be found to have small liver or peritoneal metastases at 
surgery. Hepatic metastases are seen as ill-defined low density lesions on the venous phase of contrast-
enhanced CT or MRI. Even when seen, lesions less than 10 mm may not be characterized with certainty 
on CT. These should not be considered metastases, since the majority of such small lesions, even in a 
patient with PDAC, are benign. In this respect, MRI is superior to differentiating a small cyst or hemangioma 
from metastases.  
 
Endoscopic Ultrasound  
EUS is the most sensitive nonoperative imaging test for the detection of benign or malignant pancreatic 
lesions with reported sensitivities of over 95% in most studies.18 This excellent sensitivity has provided the 
rationale for its use (along with MRI) in screening high risk individuals for PDAC.12,19-23 EUS is particularly 
useful for identification of small tumors (≤20 mm in diameter), that have been undetected by other imaging 
modalities.24,25 We recommend, therefore, that EUS should be performed in all patients with non-calculous 
obstructive jaundice in whom CT or MRI does not definitively identify a pancreatic lesion, both to detect any 
tumor and to exclude non-neoplastic diseases. A normal pancreas by EUS examination essentially rules 
out PDAC, but follow-up EUS or other study should be undertaken when EUS demonstrates chronic 
pancreatitis without a definite mass.26,27 EUS may also fail to identify true pancreatic masses in patients 
with a diffusely infiltrating carcinoma, recent episode (<4 weeks) of acute pancreatitis or indwelling biliary 
stent.28 Imaging-based technologies such as contrast-enhanced EUS and elastography have been used 
widely in Europe and Asia to aid in differentiation of pancreatic masses.29-32 These techniques are not used 
in our center and much in the United States due to high cost, lack of both contrast agent and elastography 
software availability and minimal expertise. 
EUS and multidetector CT are equivalent at determining surgical resectability of PDAC.24,25 Nevertheless 
we perform EUS and cross-sectional imaging (CT or MRI) at our center to stage most patients with known 
or suspected PDAC.  Although the TNM staging system is widely utilized for staging of PDAC, we believe 
that dividing these patients into resectable, borderline resectable, locally advanced and metastatic 
categories is more clinically useful. Resectable cancers have no vascular or regional spread which would 
contraindicate surgery. Borderline cancers have regional spread into vessels (i.e. portal vein) or other 
organs (i.e. stomach) which would make surgery difficult but not impossible (i.e. with vein removal and 
reconstruction or partial gastrectomy, respectively  -- see Figure 3). Locally invasive cancers are not 
metastatic but have invasion into structures (eg. celiac artery) which make curative surgery impossible. 
Metastatic tumors are surgically incurable due to spread to distant sites (i.e. lung, liver). EUS may detect 
and sample metastatic liver masses, ascites or distant lymph nodes missed by other imaging studies and 
therefore meticulous search for these lesions should be done during these exams.33,34 
 
Role of Tissue Diagnosis Prior to Decompression 
 
The presence of a mass in the head of the pancreas on cross-sectional imaging with a “double duct sign” 
(dilated bile and pancreatic ducts), intrahepatic lesions, and/or lymphadenopathy is specific for PDAC in 
the appropriate clinical context. However, a degree of uncertainty will remain as benign disease at the time 
of pancreaticoduodenectomy is found in up to 15% of patients. Chronic pancreatitis with inflammatory 
pseudotumor, sequalae of severe acute pancreatitis and Type I autoimmune pancreatitis (AIP) all may 
display radiographic features that overlap PDAC and can also present with jaundice. The incidence of 
autoimmune pancreatitis approaches 40% in resected specimens ultimately found to have benign disease. 
In addition, lymphoma localized to the pancreas, pancreatic neuroendocrine tumor, and metastatic disease 
to the pancreas from distant primary lesions (renal cell carcinoma, breast and lung cancer) are conditions 
with natural histories that diverge from PDAC. We perform EUS-guided fine needle aspiration (FNA) or 
occasionally fine-needle biopsy (FNB) of almost all suspicious pancreatic masses to aid in diagnosing these 
lesions, if therapeutic decisions may be altered knowing the pathology result. In some patients with 
suspected resectable PDAC, it is reasonable to proceed directly to surgery without EUS or a tissue 
diagnosis. However, if the diagnosis remains uncertain, alternative diagnoses are considered, or 
neoadjuvant therapy (and therefore biopsy) is required, then EUS-FNA should be performed. Specimens 
are obtained using a linear array echoendoscope and a 19, 22 or 25 gauge needle. The sensitivity of EUS-
FNA for the diagnosis of pancreatic malignancy is 85-90% with a specificity approaching 100%.35 
Complications are infrequent but may include pancreatitis in 1%.36  EUS-FNA is now the standard of care 
for establishing a diagnosis when uncertainty remains and can be performed at the same session as 
endoscopic retrograde cholangiopancreatography (ERCP) to render a tissue diagnosis. We utilize on-site, 
in-room cytopathologic confirmation at our institution, a practice which aids the endosonographer in 
determining the number of passes required. Consensus guidelines37 recommend preliminary tissue 
diagnosis in patients that are borderline resectable or if AIP is suspected. A diagnosis prior to or at the time 
of ERCP also plays a role in a cost effective decompression strategy as discussed below.   
Stage and Surgical Candidacy 
 
In select cases, early stage, resectable PDAC identified in patients with a pancreas head/uncinate mass 
that are surgical candidates may proceed directly to pancreaticoduodenectomy even in the presence of 
symptomatic biliary obstruction. Procedure related complications of post-ERCP pancreatitis, hemorrhage 
(early) and stent occlusion with cholangitis (late) can further delay pancreaticoduodenectomy. Studies have 
failed to demonstrate that routine pre-operative biliary decompression improves operative outcomes in 
resectable patients with PDAC. More importantly, routine pre-operative decompression is associated with 
greater pre-operative and post-operative morbidity in prospective studies. A recent prospective, 
randomized controlled trial (RCT) demonstrated a higher rate of serious complications (74% vs 39%, 
p<0.001), greater frequency of hospitalizations, with an average of 2 additional hospital days in patients 
that underwent preoperative ERCP decompression for a period of 4-6 weeks compared to patients that 
proceeded directly to surgery at <1 week.38 However, biliary decompression was achieved with plastic 
stents in this study, and patients with deep jaundice (bilirubin > 14.6 mg/dl) were excluded. We proceed 
directly to surgery without biliary decompression in surgically-fit, resectable patients without deep jaundice 
or in those who are minimally symptomatic (eg. without intense pruritus), in the absence of plans for 
preoperative neoadjuvant therapy (see below). Preoperative ERCP with biliary decompression offers 
metabolic benefit for surgical candidates with deep jaundice, warranting the procedure. The majority of 
patients (>75%) with PDAC, however, are not resectable at presentation and biliary decompression is 
appropriate for the palliation of symptoms and/or to facilitate chemotherapy and/or radiation. One caveat is 
for patients with intrahepatic metastatic disease, as jaundice should be carefully assessed for radiographic 
evidence of biliary obstruction (i.e. duct dilation). In the setting of overwhelming intrahepatic metastatic 
disease and absence of duct dilation, jaundice is more likely due to compromised hepatic synthetic function 
and biliary decompression would be unlikely to benefit the patient.  
 
Establishing Biliary Drainage for the Jaundiced Patient 
Jaundice (often painless) is the most common symptom at presentation (>50%) in patients with a new 
diagnosis of PDAC. The mechanism is due to compression/invasion of the bile duct from a peri-
ampullary/head mass which is found in > 60% of patients.39,40 Pruritus, fatigue and fat malabsorption follow 
from an obstructed bile duct and endoscopic decompression translates to an improved quality of life.39-45 
Resolution of jaundice (<2.5mg/dL) is also requisite for chemotherapy, as unacceptable chemotoxicity may 
result without adequate biliary excretion of metabolites.41 However, selecting an approach for 
decompression of malignant biliary obstruction is complex and must take into consideration: 1) an available 
confirmatory tissue diagnosis, 2) both surgical candidacy and anticipated timing of resection and, 3) life 
expectancy of the patient. This decision is best undertaken with input from a multi-disciplinary team of 




ERCP for decompression of malignant biliary strictures has a technical success rate of >90% and risk of 
complications <5% in experienced hands and is considered the standard of care.41 Predominantly 
performed in the outpatient setting, ERCP has a shorter recovery period, lower relative expense, rate of 
complications and morbidity when compared to surgical or radiologic/percutaneous interventions for biliary 
decompression.  
 Polyethylene stents (plastic) are an inexpensive, effective means of biliary decompression when placed at 
ERCP. They are easily extracted endoscopically and at the time of resection if subsequently performed. 
When plastic stent placement is pursued, 10 Fr stents are considered optimal, as comparative studies have 
failed to demonstrate greater advantage with 11.5 Fr stents,46 and smaller 7 Fr and 8.5 Fr stents offer 
negligible technical advantage in terms of ease of deployment.47 
 
Plastic stent exchanges are often necessary, as these stents inevitably occlude due to bacterial biofilm 
formation. When these plastic stents are placed, we follow an “on-demand” stent exchange protocol, 
repeating ERCP only when the patient develops recurrent signs or symptoms of biliary obstruction, as 
scheduled stent exchanges offer no additional advantage.40 Recent data suggest stent failure may occur 
at even earlier time intervals in patients with locally advanced/borderline resectable PDAC receiving 
preoperative chemotherapy. A study evaluating patency in this population reported a “premature” stent 
failure rate of 35% (median patency 49 days, IQR 25-91), with 45% of patients having an unplanned 
hospitalization.48  Stent lengths greater than 7 cm were also associated with failure in this study cohort (48 
vs 24%, p<0.01).  
 
Self-expandable metallic stents (SEMS) are mesh (steel or nitinol) prostheses that range from 6 to 10mm 
in diameter. However, 6mm stents are rarely used due to suboptimal patency rates. Proprietary designs 
vary by manufacturer in terms of mesh cell configuration and deployment systems. Covered (cSEMS) and 
uncovered (uSEMS) designs offer important advantages and disadvantages, with the principle 
differentiation being that uSEMS embed within biliary epithelium and typically cannot be removed. A tissue 
diagnosis is therefore desired prior to deployment of uSEMS, but may not be considered imperative, if 
patient management and decision-making will not be affected (eg. proceeding with surgery). Prospective 
studies and meta-analyses of jaundiced patients with PDAC treated by SEMS demonstrate superior 
duration of patency and need for fewer subsequent interventions compared to plastic stents.40,49-54 Figure 
4 illustrates SEMS placement in a patient with PDAC causing pancreatic and bile duct obstruction. Limited 
data suggest that cSEMS may have slightly longer patency rates than uSEMS, however this is not definitive 
and the increased cost of cSEMS may nullify this slight benefit.55-57 Universal use of SEMS are tempered 
by the cost added to the procedure, as metallic stents carry orders of magnitude greater expense than 
plastic stents. However, a recent prospective, randomized study evaluating plastic, uncovered and partially 
covered stents in patients within unresectable PDAC found no difference in mean total costs between 
groups (6906, 7039 and 5801 Euro, respectively, p=0.28) when accounting for follow up procedures and 
subsequent hospitalizations.49 Subgroup analysis for patients with shorter survival (<3 months) and 
metastatic disease, also showed no differences in total costs. Based on these data, the upfront expense of 
SEMS may be offset by superior stent patency and lower costs associated with subsequent hospitalizations 
and procedures.48,49,58-60 Currently, we tend to place uSEMS as first-line therapy in most cases, as 
suggested in Figure 5. In addition, when pre-operative neoadjuvant chemotherapy is being considered 
(see below, Surgical Approaches to PDAC), compelling evidence indicates that self-expanding metal, not 
plastic stents should be used, as complication rates (particularly time to first stent occlusion) are much 
higher in the plastic group. 
 
Endoscopic options when an attempted ERCP decompression fails 
 
Rates of adequate biliary drainage at first ERCP range from 70% to >90%. Factors associated with success 
include a patent gastric outlet, procedure volume at the performing center61,62 and familiarity with advanced 
techniques for ERCP biliary access (e.g. pre-cut sphincterotomy).62-65 A repeat ERCP attempt at a tertiary 
center is an appropriate next step that meets with clinical success in the majority of repeat procedures.64,66,67 
Percutaneous transhepatic biliary drainage (PTBD, see further discussion below) remains an established 
option when ERCP fails, with high levels of clinical success in the setting of dilated biliary radicals, and the 
possibility to convert to internal drainage with subsequent radiologic or endoscopic procedures.   
 
EUS-guided biliary drainage (hepaticogastrostomy, choledochoduodenostomy) is an emerging technique 
encompassing endosonographic guided transluminal stenting of the biliary tree and has reported rates of 
clinical success of (>90%) in some series. However, rates of complications can approach 10% and a 
substantial learning curve exists for performing these procedures effectively and safely. EUS-guided 
rendezvous procedures utilizing the sonographic antegrade advancement of a guidewire across the papilla 
following needle puncture of the dilated biliary tree to facilitate ERCP cannulation also reports clinical 
success rates between 70-100%. However, rates of complications also are similarly high, 3-15%.68 
Preliminary experience at expert centers suggests possible advantages of these techniques over PTBD 
with fewer follow-up procedures and lower total cost for biliary decompression.68-77 Further studies are 
required to establish the utility of these EUS-guided interventions.   
 
Percutaneous Transhepatic Biliary Drainage 
 
PTBD provides biliary decompression for patients with malignant biliary obstruction who are not candidates 
for ERCP due to anatomy-altering surgical procedures or have failed attempted endoscopic stent 
placement. As the volume of the right liver is usually greater than that of the left, PTBD to treat extrahepatic 
or hilar biliary obstruction (as from metastatic PDAC) is usually attempted from the right. In several 
instances, a left-sided approach is preferred. The right hepatic duct is typically shorter than the left and thus 
is more susceptible to isolation of the right anterior and posterior divisions when malignant obstruction 
extends above the hepatic hilum. In these cases, left-sided access may allow drainage of a greater volume 
of functional liver with a single catheter.78 Similarly, if unilateral right hepatic atrophy occurs due to portal 
vein attenuation or thrombosis, drainage of the contralateral still functional left liver will provide greater 
benefit.79 Patients with ascites may experience leakage around a percutaneous drainage catheter that can 
cause skin irritation. Left-sided drainage using an anterior rather than a right midaxillary line transhepatic 
approach will minimize gravity-dependent leakage of ascites. Last, colon overriding the right liver may 
necessitate left-sided access. 
 
PTBD is performed using fluoroscopic guidance and initial percutaneous transhepatic cholangiography 
(PTC) to evaluate biliary anatomy and the location of the obstruction. Ultrasound may be used to guide 
initial bile duct puncture, especially if ducts are dilated by downstream obstruction. Contraindications for 
PTC and PTBD include bleeding diatheses, severe ascites, intrahepatic ductal obstructions due to diffuse 
hepatic parenchymal metastases, and chronic liver disease. PTBD can be accomplished using one of three 
types of devices: an external biliary drainage catheter, an internal-external biliary drainage catheter, or an 
internal SEMS.  
 
Percutaneous external biliary drainage catheters traverse liver parenchyma to enter a bile duct and place 
drainage holes above the obstruction to allow bile to flow via gravity into an external drainage bag. These 
drains are used for high-grade biliary obstructions that cannot be crossed by a wire, as a means of initial 
decompression prior to staged internalization once edema resolves, or as temporary decompression before 
definitive surgical treatment.  
 
Percutaneous internal-external biliary drainage catheters are longer and therefore more stable. These 
catheters traverse liver parenchyma to enter a bile duct and place drainage holes above the obstruction, 
but also traverse the obstruction and major papilla or biliary-enteric anastomosis to allow bile to flow via the 
catheter into bowel and reestablish normal enterohepatic circulation. Internal-external catheters can also 
provide external drainage into a gravity bag.  Except in cases of high bile output, sepsis, or enteric 
obstruction, efforts are made to “cap” the external portion of the catheter to force antegrade internal flow of 
bile into bowel. When capped, a patient needs to be monitored for fever, leakage, or elevation of the serum 
bilirubin, in which case the internal-external drainage catheter is uncapped to external gravity drainage.80  
 
Following PTBD, patients should be monitored for signs of bleeding or infection. Despite prophylactic 
antibiotic coverage, sepsis may be seen during or within hours after PTBD.81 As bile ducts travel alongside 
hepatic arteries and portal veins in portal triads, transient hemobilia during catheter exchange may result 
when blood enters a bile duct. Sudden onset of bleeding following PTBD or any demonstrated abnormality 
of a hepatic arterial branch such as a pseudoaneurysm adjacent to a catheter should be considered 
presumptive evidence of arterial injury and should be treated with selective bracketing embolization of the 
artery across the level of injury.82 Leakage of bile around the percutaneous catheter back to skin is 
commonly due to catheter sidehole occlusion or malposition due to internal migration leaving no holes 
above the obstruction or respiratory variation retracting holes out of the bile ducts into hepatic parenchyma. 
This usually resolves following exchange for a properly positioned catheter. Additional complications of 
PTBD can include hemoperitoneum, hemothorax, pneumothorax, bile peritonitis, pancreatitis, and 
cholangitis.  
 
Percutaneous internal-external and external drainage catheters maximize biliary flow or diversion, but 
require maintenance, including emptying of drainage bags and flushing to maintain patency.83 Outpatient 
exchanges for occlusion, migration or malposition, or leakage are easily performed with moderate IV 
sedation. Following percutaneous access to the obstructed biliary tree, a lower maintenance option is 
placement of an internal SEMS across the obstruction. SEMS placement reestablishes drainage of bile into 
the bowel without the need for an external device, improving quality of life. SEMS occlusion (by tumor 
ingrowth, proximal or distal tumor overgrowth, biliary sludge) can be treated endoscopically, reserving 
additional percutaneous intervention for endoscopic failures.84,85  
 
Percutaneously-placed SEMS should only be used when placement leaves no effectively or impendingly 
isolated ducts that would be at risk for cholangitis. Ductal systems are completely isolated when PTC 
contrast does not opacify the ducts. Ducts are effectively isolated when opacified with contrast that does 
not empty on delayed imaging. Ducts may show impending isolation if central stenosis allows opacification 
and delayed emptying but is likely to progress to complete isolation. Unlike completely isolated ducts, ducts 
with effective or impending isolation are at increased risk of cholangitis because their poorly draining bile 
ducts may become colonized when contrast material enters during PTC. To decrease the likelihood that 
isolated ducts require additional intervention, SEMS should not be placed until all contaminated segments 
of the biliary tree are successfully drained or until patients are afebrile for at least 48 hours after 
discontinuing antibiotics. Percutaneous internal-external catheters can be used to treat remaining isolated 
segments.86 
 
While both percutaneous internal-external drainage catheter and SEMS placement are safe and effective 
when initial ERCP is unsuccessful, an alternative approach to percutaneous drainage alone is the combined 
interventional radiology and ERCP rendezvous procedure.87 Similar to the EUS-ERCP rendezvous 
procedure described above, antegrade cholangiography defines the level of biliary obstruction, followed by 
advancement of the guidewire across the obstruction into the duodenum. Using endoscopic guidance, the 
wire is then snared and used for retrograde access to the common bile duct, facilitating plastic or metal 
stent placement. This multidisciplinary approach is effective in patients with severe obstruction or complex 
anatomy. 
 
Surgical Approaches to PDAC 
 
Proper selection for operative resection remains paramount in the modern era of multidisciplinary 
management of patients with PDAC. High-resolution CT with dual-phase contrast enhancement is the ideal 
imaging modality for staging PDAC and determining the surgeon’s ability to achieve a complete resection 
with negative tissue margins on final pathologic assessment. Figure 6 lists the CT criteria for determining 
PDAC resectability based on preoperative imaging. Historically, patients with resectable CT criteria were 
offered operation as the first modality of therapy followed by adjuvant chemotherapy or chemoradiotherapy. 
The dismal long-term disease-free survival rates for patients who undergo an operation-first strategy for 
resectable cancer have reinforced the need for clinical trials and the development of more effective systemic 
and targeted therapies for PDAC. Recent advances in the efficacy of systemic chemotherapy agents have 
further supported the hypothetical benefits of preoperative neoadjuvant chemotherapy even for resectable 
PDAC (Table 1). Patients with borderline or locally advanced PDAC based on CT criteria should receive 
preoperative chemotherapy or chemoradiotherapy. Ideally, patients in these high-risk categories of disease 
should be offered enrollment in clinical trials investigating novel treatment agents. Despite newer systemic 
regimens which carry response rates nearing 40%, the vast majority of patients with locally advanced 
cancer will not be eligible for operative resection.88,89 Figure 7 outlines our institution’s approach to patients 
with PDAC after complete cancer staging and determination of resectability based on local vascular 
involvement according to CT findings. 
 
Once a patient with PDAC comes to resection, the surgeon’s goal is to achieve R0 resection- complete 
tumor extirpation with no evidence of macroscopic or microscopic disease at the resection margins. With 
pancreatic head resection, the most challenging margin to clear in general is the so-called retroperitoneal 
soft tissue margin (superior mesenteric artery margin). Systematic review of margin status is challenging; 
however, most studies suggest that R1 resection (microscopic disease remains in situ) or R2 resection 
(gross evidence of disease) is associated with decreased long-term survival.90 With the primary goal of 
tumor clearance in mind, pancreatic surgeons have looked to extended lymphadenectomy and vascular 
resection.  
 
Attempts to improve survival by extending lymphadenectomy have failed. One Italian and two United States 
prospective, randomized trials of extended lymphadenectomy versus standard lymphadenectomy failed to 
show survival benefit in the extended lymphadenectomy group.91-93 This extended lymphadenectomy group 
did manifest substantially increased perioperative complications. Therefore, our current practice includes 
standard lymphadenectomy with pancreatic resection. 
 
Vascular resection – specifically of the superior mesenteric vein and portal vein – is now being applied 
commonly by experienced pancreatic surgeons. This degree of extended local resection permits operative 
treatment of what had previously been considered locally advanced and unresectable disease.  Early 
enthusiasm for arterial (superior mesenteric artery and hepatic artery) resection has been tempered.  Single 
center analysis from high volume, experienced pancreatic surgery programs document no difference in 
mortality with venous resection, though these patients routinely have greater perioperative morbidity than 
those without vascular reconstruction. More recently, nationwide survey data from the United States 
National Surgical Quality Improvement Project suggest that venous resection may indeed be accompanied 
by higher mortality.94 Most authorities agree that this technique should be practiced in higher volume 
centers with surgeons experienced in both pancreatic surgery and vascular reconstructive techniques. Our 
current practice applies venous resection and reconstruction to approximately 20% of patients undergoing 
pancreatic resection.95  
 
Mortality after pancreatectomy has decreased substantially in recent years. Advances in operative 
technique, critical care, and perhaps most importantly the ability of high-volume centers to rescue patients 
after major complication have led to contemporary post-operative mortality rates consistently in the 2%-3% 
range.95 Despite decreases in mortality, post-pancreatectomy morbidity remains relatively high, on the 
order of 30%-40%96,97 even at many high-volume centers, including our own.90,95,98 Common complications 
after pancreatic resection include bleeding, delayed gastric emptying,99 and fistula from any of the three 
enteric anastomoses:  gastrojejunostomy, hepaticojejunostomy, and pancreaticojejunostomy.99-102 The 
international study group for pancreatic surgery (ISGPS) has published consensus definitions for many of 
these complications, facilitating standardized communication among reporting centers.103-105 Among all 
post-pancreatectomy complications, pancreatic fistula remains the most common, and the Achilles’ heel of 
the operation. Pancreatic fistula occurs approximately 15% of patients after pancreatic head resection 
(pancreatoduodenectomy) and in about 25% of patients after left-sided pancreatic resection (distal 
pancreatectomy).102,106 The greatest risk factor for pancreatic fistula development is a normal pancreas, 
with soft parenchyma and a small pancreatic duct.107 Thankfully, most pancreatic fistulae will heal with 
minimal additional intervention. However, these fistulae may lead to significant problems including intra-
abdominal abscess, hemorrhage, and death. In fact, more than half of the mortality after pancreatectomy 
can be related directly to pancreatic fistula. The key to managing pancreatic fistula is controlled external 
drainage. To this end, prospective, randomized data highlight the utility of intraoperative drain placement 
in pancreatectomy.108 Patients with externally controlled pancreatic fistulae may continue along common 
post-operative management pathway – i.e. have diet advanced liberally, and are discharged from the 
hospital with the drain in situ. After a few weeks’ time to permit intraabdominal adhesions around the drain, 
the drain may be “cracked” or withdrawn a few centimeters. Drainage typically slows, and the drain may 
then be removed. Some surgeons prefer to perform “sinogram” – injecting contrast through the drain - prior 
to removal. Occasionally, persistent pancreatic fistula after distal pancreatectomy may require ERCP with 
stenting to assist closure. Uncontrolled pancreatic fistula may present with abdominal distention, vomiting, 
fever, and signs of SIRS. Cross sectional imaging (CT) will diagnose undrained intra-abdominal collections, 
many of which are amenable to percutaneous interventional radiology drainage. Occasionally, reoperation 
is required to gain control of pancreatic fistula.   
 Despite substantial technical improvements in the conduct of pancreatic resection, patients continue to die 
from recurrent disease even after a “perfect” operation. These disappointing observations underscore the 
need for improved systemic therapy.  
 
Systemic therapy for patients with pancreatic cancer 
 
Management of resectable disease 
 
Only a small fraction of patients with PDAC present with resectable disease. Median overall survival (OS) 
for these patients is 20-22 months.109,110 These patients are offered surgical resection followed by adjuvant 
chemotherapy or chemoradiotherapy (the radiotherapy being controversial and generally done more in the 
United States than in most of Europe). However, due to the fact that 5-year survival of this group is 10% 
with surgery alone and 25% with the addition of adjuvant therapy,111 preoperative neoadjuvant 
chemotherapy has been proposed112,113  (as outlined in Surgical Approaches to PDAC, and Table 1). The 
challenge to this approach is a lack of effective systemic therapies. A meta-analysis summarized several 
neoadjuvant studies and demonstrated an actual resection rate of 70% in patients with initially 
radiographically resectable PDAC.113 Resection after neoadjuvant therapy appears to be safe.114 In a 
prospective phase II study, patients who underwent neoadjuvant, gemcitabine based, chemoradiotherapy 
had a median OS of 34 months and a 5-year survival of 36%.115 Adjuvant chemotherapy with gemcitabine 
in comparison to observation after surgical resection improves disease-free survival, OS and 5 year OS.  
5-fluorouracil (5-FU) with leucovorin has been compared to gemcitabine in the adjuvant setting and was 
equally effective.110 However, due to the more manageable toxicity profile associated with gemcitabine, it 
is the preferred adjuvant chemotherapy choice throughout much of the world. Currently at Indiana 
University, we are conducting a prospective phase II study of neoadjuvant FOLFIRINOX (5-FU, leucovorin, 
irinotecan, and oxaliplatin) for two months in patients with apparently resectable disease by radiographic 
criteria. Patients are initially discussed by our multidisciplinary tumor board which involves colleagues from 
several disciplines (medical and radiation oncology, surgery, gastroenterology). This helps stratify patients 
based on their stage, with discussion regarding the possibility of surgical resection, should downstaging be 
accomplished. Furthermore, patient eligibility for therapeutic or biomarker clinical trials may also be 
coordinated.  
 
Management of borderline resectable and locally advanced unresectable PDAC 
 
The optimal management of this group is controversial. Up to 70% of patients with locally advanced disease 
die of metastatic disease116 and therefore, a systemic approach is more favorable. Combination 
chemotherapy with radiation therapy has yielded controversial results, especially in the absence of 
predictive biomarkers.117-119 Although highly selected patients with borderline or locally advanced PDAC 
have gone on to surgical resection,120 this phenomenon remains uncommon. One goal of therapy in 
borderline resectable disease cancer is to induce significant response to allow surgical resection. A recent 
pilot study by the U.S. Alliance cooperative group evaluated the feasibility and safety of modified 
FOLFIRINOX followed by external beam radiotherapy in combination with capecitabine.121 This strategy 
appears to be feasible, and resulted in a high rate of R0 resection in patients who completed preoperative 
therapy without evidence of progression. Several questions remain to be addressed regarding the role of 
radiation therapy, the duration of chemotherapy, and the optimal regimen of systemic therapy.  
 
Management of metastatic disease 
 
For the last two decades, gemcitabine was the only real option for the management of patients with PDAC. 
This was based on early data demonstrating improved pain control and decreased rate of weight loss with 
gemcitabine.122 The survival benefit of gemcitabine over 5-FU was quite modest. More recently, 
combination cytotoxic chemotherapy has shown improved progression-free survival (PFS) and OS over 
gemcitabine alone. FOLFIRINOX has demonstrated improvement in PFS from 3.4 months to 6.6 months.88 
Similarly, OS was improved with FOLFIRINOX (6.7 to 11.1 months). This improvement was associated with 
increased toxicity, but despite this, quality of life was preserved for a longer duration in patients treated with 
FOLFIRINOX.123 The first combination therapy to be approved by the FDA was the combination of 
nanoparticle albumin bound paclitaxel (nab-paclitaxel) in combination with gemcitabine. Similarly, this 
combination improved PFS (3.3 months to 5.5 months) and OS (6.7 to 8.5 months).89 Quality of life studies 
were not conducted with this combination therapy.  
 
At our institution, the approach to systemic therapy depends on the patient’s symptoms, performance 
status, and comorbidities. For patients with good ECOG (Eastern Cooperative Oncology Group) 
performance status, clinical trials are preferred when available. If not, FOLFIRINOX or nab-
paclitaxel/gemcitabine is commonly offered.  At the time of progression on first line therapy, patients with 
maintained performance status are typically treated with 5-FU based-therapy or FOLFOX if they received 
initial gemcitabine-based therapy,124 or gemcitabine-based therapy if 5-FU-based therapy was used first 
line.  
 
Radiation therapy for PDAC 
 
Radiation treatment (RT) paradigms for PDAC are constantly evolving with the development of more active 
chemotherapy regimens and continuing advances in radiation planning and delivery techniques.  Treatment 
decision-making in patients with PDAC has been shaped by a series of ongoing controversies regarding 
the role of RT in managing this disease as well as by technological advances in imaging, radiation planning, 
and treatment delivery. 
 
Vigorous debate continues within gastrointestinal oncology regarding the optimal adjuvant therapy for 
patients with PDAC. Although early results published in the 1980’s reported a survival benefit with the 
postoperative delivery of 40 Gy split-course adjuvant RT plus 5-FU,125 subsequent European studies 
suggested that at best, no clinical benefit was associated with postoperative treatment, and that at worst, 
adjuvant RT was associated with worse outcomes. ESPAC-1 tested postoperative chemotherapy alone, 
chemoradiation, chemotherapy followed by chemoradiation, and observation in patients with resected 
PDAC and reported shorter survival in patients treated with chemoradiation compared to those who 
received chemotherapy.126 This was not truly an RCT, as clinicians were allowed to select the randomization 
arm that the patients would enter; furthermore, there was considerable crossover between arms, and the 
study lacked centralized quality assurance practices. EORTC 40891 tested 40 Gy split-course RT plus 5-
FU vs. observation in patients with both pancreatic and periampullary cancers.127 This study showed a non-
significant trend toward improved OS in the treatment group, with a suggestion that patients with pancreatic 
head tumors may have derived a greater benefit from treatment than those with ampullary tumors. Like 
ESPAC-1, the results of this trial should be interpreted cautiously, given its use of an outdated radiation 
regimen and lack of radiation quality assurance procedures. Furthermore, the inclusion of only patients with 
relatively early stage (T1-2/N0-1) pancreatic tumors and the pooling of patients with pancreatic and 
periampullary lesions in the same study may also have reduced the likelihood of observing a significant 
benefit from adjuvant RT in this trial. 
 
Several more recent studies have attempted to answer the questions raised by these earlier trials. RTOG 
9704 randomized patients to receive either induction gemcitabine or 5-FU plus adjuvant chemoradiation 
therapy (50.4 Gy/5-FU) and reported no significant difference in OS between the two treatment arms.128 At 
virtually the same time, a German study (CONKO-001) investigated adjuvant gemcitabine alone (vs. 
placebo) and reported an absolute benefit in 5 year OS of approximately 10% (with 5-year OS times of 20.7 
vs 10.4% in the gemcitabine and placebo arms, respectively).111 Survival outcomes in RTOG 9704 and 
CONKO-001 were comparable, supporting the contention that chemotherapy alone (rather than 
chemoradiation) may be an acceptable adjuvant therapy option in patients with resected PDAC. 
Nonetheless, postoperative RT should still be considered in selected patients, given the restrictive eligibility 
criteria of CONKO-001 (which required postoperative CA19-9 levels to be under 90 IU/mL), the relatively 
high local failure rates when RT is omitted, and pooled data from high-volume US centers suggesting that, 
in experienced hands, adjuvant radiation therapy does indeed provide a survival benefit to well-selected 
patients with resected PDAC.129 Ongoing efforts to improve patient selection for adjuvant treatment are 
exemplified by the ongoing US cooperative group study, RTOG 0848, which delivers RT only in patients 
whose disease does not progress after five cycles of adjuvant chemotherapy (plus or minus erlotinib). Our 
present approach is to consider postoperative RT in patients with high-risk features such as positive 
resection margins or multiple positive lymph nodes who have not developed metastatic progression during 
the first few cycles of postoperative chemotherapy.  
 
Patients with locally advanced PDAC have high rates of occult metastatic disease and generally benefit 
from a course of induction chemotherapy before radiation therapy can be considered. In a recent 
prospective series testing this approach,130 patients were initially randomized to gemcitabine or gemcitabine 
plus erlotinib; those without progression on this regimen were then randomized to capecitabine-based 
chemoradiation versus chemotherapy alone. Forty percent of initially randomized patients developed 
progressive disease and did not proceed to the second randomization. Although the study did not 
demonstrate a benefit in OS for RT, local failure rates and time to treatment resumption were both 
significantly improved in the RT arm. We generally recommend a similar approach (i.e., chemotherapy 
followed by chemoradiation) in patients with borderline resectable disease, with surgical exploration 
planned four to six weeks after chemoradiation is completed. However, long-term tumor control and OS 
outcomes in this group of patients remain unsatisfactory, especially in patients with unresectable tumors, 
and innovative approaches to intensifying treatment are clearly needed.   
 
Stereotactic body radiation therapy (SBRT) permits radiation dose intensification via hypofractionated 
treatments that are delivered to highly focused targets using daily image guidance and respiratory motion 
control. Although phase III studies of this technique are not yet available, mature phase II studies have 
reported encouraging local control rates with a favorable acute toxicity profile.131 The primary side effect 
associated with SBRT to the upper abdomen is late gastrointestinal bleeding/ulceration. Risk factors for 
SBRT-related upper GI bleeding include the use of large fraction sizes and the presence of tumor invasion 
into the lumen of the bowel or stomach, which should be considered an absolute contraindication to the 
use of this technique in patients with PDAC.132  Presently, we recommend that SBRT be used for PDAC 
only in the context of a clinical trial. However, the therapy is promising and merits investigation for multiple 
indications in patients with PDAC, including as adjuvant therapy, downstaging for patients with borderline 
to locally advanced disease, and as an adjunct to chemotherapy and a substitute for long-course radiation 
in patients with unresectable tumors.   
 
Additional avenues for research into optimizing outcomes in patients receiving RT for PDAC include 
evaluating neoadjuvant therapy, which has significant theoretical advantages over postoperative treatment, 
even in patients with resectable disease; testing particle therapy, particularly proton-beam therapy; and 
further study of the integration of immunotherapy, such as immune checkpoint inhibitors and antitumor 
vaccines, with RT and conventional chemotherapy.  
 
Pancreatic Exocrine Insufficiency and Nutritional Support 
 Exocrine pancreatic insufficiency is a well-described phenomenon in patients with PDAC in both the pre-
operative and postoperative setting. Rates of exocrine insufficiency, lipid maldigestion and malabsorption 
as measured by a Lundh test, fecal elastase testing and 13C-trioctanoin breath testing approach 80-90% in 
patients with PDAC.133-136 Likely related to obstruction of the main pancreatic duct, maldigestion may be 
further exacerbated by biliary obstruction.134,136 Pancreatic exocrine insufficiency is also prevalent following 
resection, more frequently noted with pancreaticoduodectomy (>70%) than distal pancreatectomy (30-
60%). Indeed, pancreaticoduodenectomy and pre-operative duct diameter >10mm have been found to be 
predictors for maldigestion.136,137 Mechanisms for exocrine insufficiency following 
pancreaticoduodenectomy, beyond loss of pancreatic parenchyma, include poor mixing of chyme with 
pancreatic enzymes, impairment of exocrine pancreatic secretion from disruption of vagus branches, and 
diminished cholecystokinin and secretin stimulation after duodenal resection.136 It is a misconception that 
steatorrhea is always associated with exocrine insufficiency. Studies have demonstrated poor correlation 
between symptoms and exocrine insufficiency.136 Consequently relying on symptoms alone for decision-
making regarding pancreatic enzyme supplementation is not appropriate. Randomized studies are now 
available demonstrating weight gain and superior survival in patients with PDAC managed with pancreatic 
enzyme supplementation. However, benefit of systematic supplementation following 
pancreaticoduodectomy has not been as clearly demonstrated.136,138 This is likely due to the additional 
mechanisms for maldigestion outlined above. Bartel and colleagues136 offer a thorough review of exocrine 
insufficiency in the context of PDAC. The authors offer a cogent argument for pancreatic enzyme 
supplementation in all unresectable patients with pancreatic duct obstruction and treatment in patients 
following pancreaticoduodenctomy dictated by 72 hour fecal fat testing. Co-management of patients with a 
dietician, palliation of gastric outlet obstruction and pain and micronutrient supplementation are also 
elements of the multidisciplinary approach to management of malnutrition in patients with PDAC. However, 
beyond pancreatic enzyme supplementation, the optimal approach for nutritional support in patients with 
PDAC is a subject that is rarely discussed in available societal guidelines and requires further study. 
 
Palliation for unresectable pancreatic cancer  
 
Palliation remains the cornerstone of management of patients with unresectable PDAC and is primarily 
directed at relief of symptoms and improvement in quality of life. A tailored therapeutic approach based on 
the patient’s preferences, prognosis, life expectancy, and on the local expertise should be followed.  
 
Palliative care consultation  
 
Referral to a specialized palliative care service is often delayed because of the patients’ (and often the 
physicians’) misconception about palliative care being an alternative (rather than an additional) resource 
for anticancer treatment.139,140 Specialized palliative care service includes home-based hospice care 
programs, inpatient hospices, palliative care units, and palliative care teams. Several trials suggest that a 
combined early introduction of the specialized palliative care service, providing on-demand specialized 
palliative care, and the routine use of screening tools and feedback to the treating physicians of quality of 
life (QOL) measurements or symptom assessment scales, contribute to a better QOL for cancer patients 
receiving active cancer treatment.141-143 We recommend consideration of an early referral to a specialized 




Up to 90% of patients with PDAC experience significant abdominal pain during the course of their illness. 
The celiac ganglion is responsible for pain transmission, and interventions targeted here (percutaneous, 
endoscopic, or surgical) may offer pain relief. We favor endoscopic over percutaneous access to the celiac 
ganglion at our institution, primarily due to availability. Furthermore, limited data from a single RCT favored 
the endoscopic approach.144 Surgical intervention typically occurs in those patients who undergo a planned 
resective procedure but are found to have unresectable disease intraoperatively. When analgesia is 
suboptimal with oral/topical agents alone, or these are not tolerated, EUS-guided celiac plexus neurolysis 
(EUS-CPN) and celiac ganglion neurolysis (EUS-CGN) are achieved by injection of local anesthetic (e.g. 
bupivacaine) followed by absolute alcohol into the celiac plexus (CP) or celiac ganglia (CG). Early EUS-
CPN, at the time of diagnostic and staging EUS, provides better pain relief and may prevent pain escalation 
while moderating narcotic use.145 Pain reduction can be expected in up to 80% of patients within 2 weeks 
of the procedure.146 There are no predictive factors for pain relief after EUS-CPN, although direct tumor 
invasion of the celiac plexus is associated with reduced efficacy.147 EUS-CPN has little to no impact on 
survival compared with controls.148  
 
Bilateral (both sides of the CP) injection allows a wider distribution of the neurolytic solution in the area of 
the celiac axis. While there has been discordance between studies evaluating effectiveness of bilateral 
versus unilateral injections,149,150 a meta-analysis suggested superiority of bilateral injection over unilateral 
injection.151 In addition, a recent multicenter RCT showed superiority of EUS-CGN over EUS-CPN for the 
palliation of pain; however, the comparison was not against bilateral injection and the response rate with 
CGN vs unilateral was similar to the bilateral vs unilateral technique.152) 
 
Data on adverse events of EUS-CPN are limited to small retrospective series and case reports.146 Mild 
complications include transient diarrhea (4-15%), hypotension (1%), and increase in pain (9%). Major 
complications (2.5%) include retroperitoneal bleeding and abscess formation. In our practice and in view of 
the relative efficacy and safety, we recommend early consideration of EUS-CPN for patients with 
unresectable PDAC with opiate-requiring abdominal pain.   
 Gastric outlet obstruction (GOO)  
 
GOO is a surrogate marker for poor survival in patients with unresectable PDAC, occurring in 10-25% of 
patients. It can cause significant morbidity through persistent intractable nausea and vomiting, malnutrition, 
and weight loss. Historically, treatment has consisted of an open or laparoscopic surgical bypass i.e. 
gastrojejunostomy (GJ). However, some patients are not surgical candidates, either because of their overall 
physical status or limited life expectancy. Similar to biliary SEMS, enteral SEMS have emerged as a non-
surgical alternative in these patients (Figure 8). A recent systematic review and meta-analysis of 3 RCTs 
and 17 non-RCTs of endoscopic stenting versus operative GJ (open or laparoscopic) was conducted.153 
Taking all studies as a whole, patients who received endoscopic SEMS had significantly fewer major and 
minor complications, a shorter time to tolerance of oral intake, and a shorter hospital stay. In the non-RCTs, 
there was also a trend towards lower medical costs (mean $8,629 vs $17,842; p = 0.09) in the SEMS group. 
There was no difference in median survival time among RCTs and non-RCTs and in quality of life.153,154 
 
Mild early adverse events of gastroduodenal SEMS include abdominal discomfort, nausea, and vomiting. 
These symptoms can be related to a delayed full-expansion of the stent, which may take up to one week, 
and are typically treated conservatively. As early stent obstruction may occur from food particles, we 
typically ask patients to follow a liquid diet for a few days post-stent placement, to be advanced as tolerated 
to a low residue diet indefinitely. Major adverse events are rare but may be early or delayed. Those 
occurring within the first week include severe pain, bleeding, perforation, and stent migration. Late adverse 
events include fistula formation, delayed perforation, biliary obstruction, and stent migration.41,80 Stent 
obstruction occurs in 15-20% of patients and typically results from tumor in- or overgrowth. This can be 
treated with placement of a second stent, either within or overlapping the first stent. Partially covered, fully 
covered, and conformable stents represent an alternative to uncovered SEMS.155-157 These are not 
available in the United States and are associated with higher migration rates.  
 
If possible, the distal end of the SEMS should be left proximal to the major papilla, allowing for future biliary 
interventions if needed. The specific location of the GOO and gastroduodenal anatomy, however, impact 
the length of SEMS necessary and this may not be possible. In this case, in order to treat biliary obstruction, 
either present or impending at the time of GOO diagnosis, we usually attempt endoscopic biliary drainage 
prior to deployment of duodenal stents. If simultaneous biliary and duodenal SEMS placement is not 
possible, and the distal end of the duodenal SEMS crosses the major papilla, subsequent biliary 
decompression via ERCP may be very difficult, as the papilla is obscured and distorted by the SEMS. While 
it may be possible to attempt endoscopic biliary drainage through the interstices of the enteral stent or by 
fenestration of the stent (using a rat toothed forceps or argon plasma coagulation), these maneuvers 
frequently fail. In these cases, percutaneous or EUS-guided (transhepatic or transduodenal without 
accessing the papilla or via rendezvous with ERCP) options are available,158 pending local expertise (see 
above, Establishing Biliary Drainage for the Jaundiced Patient), with surgical biliary drainage less 
desirable. An informed patient and discussion with the multidisciplinary team is mandatory in these cases. 
 
In summary, significant developments continue to be made in the diagnosis and management of patients 
with pancreatic ductal adenocarcinoma. These patients are best managed by a multidisciplinary team, 
consisting of gastroenterologists, pancreatobiliary surgeons, radiologists and oncologists. Advances in 
cross-sectional imaging have led to more accurate diagnosis and staging. When needed, endoscopists are 
able to provide tissue diagnosis and further staging at EUS, as well as biliary decompression at ERCP with 
a high level of success. Use of self-expandable metal stents has proven to be a cost-effective strategy. 
Furthermore, palliation of gastric outlet obstruction and debilitating pain can often be managed 
endoscopically, with enteral stent placement and EUS-guided celiac neurolysis, respectively. Surgical 
resection remains the only chance for cure in this disease, and improved surgical techniques including 
venous reconstruction may lead to an increase in the percentage of resectable patients. New chemotherapy 
protocols, with or without radiation therapy, have led to an increase in overall survival, although this strategy 
remains palliative. On the other hand, preliminary data evaluating the use of neoadjuvant chemotherapy in 
the pre-operative setting appear promising. Despite these advances and innovations, pancreatic cancer 
remains the silent killer, as most patients are not candidates for curative therapy at presentation. Further 
study is desperately needed, particularly in early detection. The discovery of a biomarker that would 
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Table 1. Rationale for neoadjuvant therapy  
• Increase likelihood of truly negative surgical margins  
• Increase likelihood of completion of all intended multimodality therapy  
• Declaration of distant metastases and early progression of disease  
• Declaration of patient’s functional status anTd inability to tolerate operation  
• Opportunities for in vivo and in vitro testing for chemoresponsiveness 
Figure Legends 
Figure 1. A 67-year-old female with persistent abdominal pain and weight loss. A. Axial CT performed 
with thick slices (5 mm) at an outside institution shows an abrupt cut-off of the main pancreatic duct 
(arrow). No obvious pancreatic head mass was seen. In addition, an ill-defined liver lesion was seen 
(black arrowhead). B. Axial CT at our institution performed as per pancreas protocol with thin slices (3 
mm) in parenchymal phase shows the duct cut-off (arrow) caused by an ill-defined low density pancreatic 
head mass (white arrowhead).  The liver lesion (black arrowhead) is shown to have a clear outline and 
was diagnosed as a benign cyst. The patient underwent pancreaticoduodenectomy for resectable ductal 
adenocarcinoma.  
 
Figure 2. 53-year-old male with painless jaundice. A. Axial post-gadolinium MRI shows a large mass in 
the pancreatic head (white arrow) closely applied to the superior mesenteric artery (SMA) (black arrow). 
The tumor was deemed unresectable due to the long length of contact with the SMA. B. Coronal CT 
performed two months later shows metal biliary (winged arrow) and duodenal (curved arrow) stents in 
place. There remains a large tumor (white arrow) which is closely applied to the SMA (black arrow) and 
celiac artery (white arrowhead). In addition, a liver metastases (black arrowhead) is seen. 
 
Figure 3. A. Schematic illustration of a mass in the body of the pancreas, visualized by EUS. B. The 
pancreas mass is abutting the portal confluence. 
 
Figure 4. ERCP images obtained in a 70 year old man with abdominal pain, diarrhea, jaundice and 
weight loss. CT scan reveals a head of pancreas mass. A. Contrast injection reveals an obstructed 
pancreatic duct and distal bile duct stricture (“double-duct sign”). B. Biliary dilation proximal to the biliary 
stricture (arrow). C. Fluoroscopic and D. Endoscopic images of a metal stent placed through the biliary 
stricture, with subsequent bile flow. 
 
Figure 5. Suggested algorithm illustrating our approach to a patient with pancreas cancer and biliary 
obstruction. 
 
Figure 6. CT criteria for determining resectability of pancreatic ductal adenocarcinoma. 
 
Figure 7. Approach to the patient with pancreatic ductal adenocarcinoma at Indiana University Hospital. 
Figure 8. This patient with metastatic pancreas cancer presents with nausea and vomiting. A. CT scan 
reveals liver metastases and a distended stomach; B. CT scan reveals the pancreas mass, a dilated bile 
duct with stent in place, liver metastasis, and a distended fluid filled stomach; C. Endoscopic image of the 
fluid-filled stomach; D. duodenal obstruction by tumor; E. catheter and guidewire passage beyond the 
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*Patients with anticipated delays of surgery > 2 weeks for work up/stabilization of comorbidities should 
undergo pre-operative decompression; significant symptoms = deep jaundice, refractory pruritus
^ EUS-FNA should be performed in patients with elevated suspicion for autoimmune pancreatitis or otherwise 
benign disease causing obstruction, or for tissue confirmation prior to planned chemoradiotherapy
PTBD: percutaneous transhepatic biliary decompression; uSEMS: uncovered self expandable metallic stent; 
cSEMS: covered self expandable metallic stent
Figure 5: Algorithm for Management of Malignant Biliary Obstruction
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